Literature DB >> 9425690

Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR).

K J Smith1, H G Skelton, J Yeager, R Ledsky, T H Ng, K F Wagner.   

Abstract

Drug reactions are common in HIV-1 disease, with the incidence having been reported to increase with increasing stage and with CD4+ T-cell counts below 200/microliters. However, there have been numerous reports of patients in which rechallenge, dosing changes or continued therapy have resulted in no recurrence or else clearing of the eruption. We followed 974 HIV-1-positive patients for 46 months as a part of a military study of HIV-1 disease. Within this group there were a total of 283 drug eruptions, with cutaneous manifestations in 201 patients in which clinical characteristics were noted and 86 patients in which cutaneous biopsies were performed. Serological evidence of reactivation or acute Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infections were also noted, as well as peripheral eosinophilia. The incidence of drug eruptions significantly increased with increasing Walter Reed stage and decreasing CD4 counts and CD4/CD8 ratio, as well as with increasing age and in patients with increased numbers of other dermatological diagnoses. In addition, white patients had significantly more drug eruptions than did black. Serological or culture evidence of acute or reactivated EBV or CMV was significantly increased in patients with drug eruptions. The majority of the eruptions were maculopapular or morbilliform with a predominantly perivascular mononuclear cell infiltrate. HIV-1 positive patients have an increased incidence of drug reactions, the incidence having been reported to increase in patients with less than 200 CD4+ T cells/microliter. However, at very low T4 counts, especially those less than 25/microliter, and at a CD4/CD8 ratio of less than 0.10, the probability of reactions to trimethoprim-sulphamethoxazole (TMP-SMZ) is decreased in late-stage HIV-1 patients. Maculopapular or morbilliform eruptions are the most common clinical presentations, often accompanied by one or more of the following: fever, arthralgias, eosinophilia, and serum transaminase elevation. Histologically the majority of these eruptions show a perivascular mononuclear cell infiltrate, sometimes with focal interface changes and apoptotic, necrotic cells within the epidermis. Acute hypersensitivity reactions and toxic epidermal necrolysis (TEN) or Stevens-Johnson's syndrome (SJS) with diffuse epidermal apoptosis and necrosis have also been less commonly described. In a study of cutaneous manifestations in an HIV-1 positive military population, drug reactions were evaluated in terms of clinical features, histopathology, demographic features and laboratory findings.

Entities:  

Mesh:

Year:  1997        PMID: 9425690

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  14 in total

1.  Cutaneous manifestations of human immunodeficiency virus: a clinical update.

Authors:  Kirstin Altman; Erin Vanness; Ryan P Westergaard
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

Review 2.  Drug hypersensitivity in HIV infection.

Authors:  Jonny Peter; Phuti Choshi; Rannakoe J Lehloenya
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-08

Review 3.  New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity.

Authors:  Aaron W Michels; David A Ostrov
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

4.  Antibiotics-related adverse events in the infectious diseases department of a French teaching hospital: a prospective study.

Authors:  J Courjon; C Pulcini; E Cua; K Risso; F Guillouet; E Bernard; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-07-23       Impact factor: 3.267

5.  Temporal trends in mucocutaneous findings among human immunodeficiency virus 1-infected children in a population-based cohort.

Authors:  Amy S Sturt; Andrew Anglemyer; David R Berk; Yvonne A Maldonado
Journal:  Pediatr Dermatol       Date:  2012-11-07       Impact factor: 1.588

6.  Oral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four cases.

Authors:  S Balasundaram; K Ranganathan; K Umadevi; R Gunaseelan; N Kumaraswamy; Sunithi Solomon; Bella Devaleenol; Pradeep Ambrose
Journal:  J Oral Maxillofac Pathol       Date:  2011-01

7.  Effect of antiretroviral therapy on mucocutaneous manifestations among Human Immunodeficiency Virus-infected patients in a tertiary care centre in South India.

Authors:  Nagendran Prabhakaran; Telanseri J Jaisankar; Abdoul Hamide; Munisamy Malathi; Rashmi Kumari; Devinder Mohan Thappa
Journal:  Indian J Sex Transm Dis AIDS       Date:  2015 Jul-Dec

8.  Mechanisms of hypersensitivity reactions induced by drugs.

Authors:  Fabrizio Franceschini; Paolo Bottau; Silvia Caimmi; Fabio Cardinale; Giuseppe Crisafulli; Lucia Liotti; Francesca Saretta; Roberto Bernardini; Francesca Mori; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2019-01-28

9.  Inadvertent Provocative Oral Ondansetron use Leading to Toxic Epidermal Necrolysis in an HIV-infected Patient.

Authors:  Punit P Saraogi; Chitra S Nayak; Rickson R Pereira; Rachita S Dhurat
Journal:  Indian J Dermatol       Date:  2012-11       Impact factor: 1.494

Review 10.  Crucial Role of Viral Reactivation in the Development of Severe Drug Eruptions: a Comprehensive Review.

Authors:  Tetsuo Shiohara; Yukiko Ushigome; Yoko Kano; Ryo Takahashi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.